Journal: Journal of the Endocrine Society

Article Title: Continuous Glucose Monitoring in Patients With Postbariatric Hypoglycemia: Effect on Hypoglycemia and Quality of Life

doi: 10.1210/jendso/bvaf106

Figure Lengend Snippet: Study design overview. Participants were first screened, randomized, and trained in CGM use. Subjects were then assigned to begin with either a 10-day unblinded CGM (Dexcom G6) or 10-day blinded CGM (Dexcom G6 Pro) period. Each monitoring phase was followed by completion of the Hypoglycemia Fear Survey-II (HFS-II), an event diary, and training (if applicable) with a new CGM device. All participants crossed over to the alternate CGM modality for another 10-day period. The study concluded with repeated HFS-II assessments, event diary entries, and CGM data download. Blinded CGM data (Dexcom G6 Pro) was used for all outcome analyses to ensure consistency.

Article Snippet: Patients with confirmed PBH were screened for eligibility and if enrolled, were assigned to 2 treatment periods given sequentially but in random order to avoid confounding by treatment order: (1) a 10-day period with use of unblinded Dexcom G6 (the intervention of interest) and (2) a 10-day control period without use of unblinded Dexcom G6 ( ).

Techniques:

Journal: Therapeutic Advances in Endocrinology and Metabolism

Article Title: Prospective multicenter evaluation of glycemic and patient-reported outcomes following transition to a next-generation continuous glucose monitoring system in users of advanced hybrid closed-loop technology

doi: 10.1177/20420188251407515

Figure Lengend Snippet: Study timeline. The schematic illustrates the study timeline, including retrospective and prospective data collection periods surrounding the transition from Dexcom G6 ® to Dexcom G7 ® (Day 0). Retrospective data collection: CGM data were retrieved at three time points before the transition (−90, −30, and −14 days), concluding the day before switching to Dexcom G7. Prospective data collection: at three time points after the transition (+14, +30, and +90 days), incorporating the day of the G7 transition in the analysis. Participants underwent two key study visits: Baseline Visit (Day 0): Included baseline questionnaires, anthropometric measurements, and HbA 1c assessment. Final Visit (+90 days): Included final questionnaires, anthropometric measurements, and HbA 1c assessment. *The day of the G7 transition is included in the prospective data downloads (+14, +30, +90). Retrospective data collection (−90, −30, −14) concludes the day before transitioning to G7. CGM, continuous glucose monitors.

Article Snippet: These functionalities have been shown to significantly improve glycemic metrics, including a 12% increase in time in range (TIR 70–180 mg/dL), reductions in mean glucose levels, a 0.38% decrease in HbA 1c , and fewer hypoglycemic episodes., Initially, the Control-IQ system was integrated with the Dexcom G6 ® continuous glucose monitoring (CGM) system, which provided real-time interstitial glucose measurements.

Techniques: